NCT04870905View on ClinicalTrials.gov

Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2026

Conditions
Nasopharyngeal Neoplasms
Interventions
DRUG

Tis-U-Sol

Tislelizumab 200mg will be given every 3 weeks for 12 cycles

Trial Locations (1)

Unknown

Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou

All Listed Sponsors
collaborator

Union hospital of Fujian Medical University

OTHER

collaborator

Zhujiang Hospital

OTHER

collaborator

Guangdong Provincial People's Hospital

OTHER

lead

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER